15
ALL15
Creative Medical TechnologyYear
15
ALL5
20252
20241
20237
2021DEALS // DEV.
15
ALL1
Deals14
DevelopmentsCountry
15
ALL15
U.S.A15
ALL1
Greenstone Biosciences14
InapplicableTherapeutic Area
15
ALL4
Cardiology/Vascular Diseases3
Endocrinology1
Infections and Infectious Diseases1
Nephrology5
Neurology1
Obstetrics/Gynecology (Women’s Health)Study Phase
15
ALL7
Phase I/ Phase II4
IND Enabling3
Preclinical1
Discovery PlatformDeal Type
15
ALL1
Collaboration14
InapplicableProduct Type
15
ALL15
Cell and Gene therapyDosage Form
15
ALL1
Intra-arterial Infusion5
Intramuscular Injection5
Intravenous Injection4
UndisclosedLead Product
15
ALL1
Allogeneic Umbilical Cord Mesenchymal Stem Cell5
Amniotic Fluid Derived Stem Cell6
CELZ-2011
Induced Pluripotent Stem Cell1
OvaStem1
UndisclosedTarget
15
ALL5
HGF-11
Stem cell proliferation1
T-cell8
UndisclosedLead Product(s) : CELZ-201
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Creative Medical’s CELZ-201-DDT Clinical Trial Expands Dose Escalation
Details : AlloStem (CELZ-201-DDT) is a cell and gene therapy drug candidate, which is currently being evaluated for chronic low-back pain caused by degenerative disc disease (DDD).
Product Name : AlloStem
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 20, 2025
Lead Product(s) : CELZ-201
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CELZ-201
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Creative Medical Reports Opioid Reduction in StemSpine® Mid-Term Study
Details : AlloStem (CELZ-201-DDT) is a cell and gene therapy drug candidate, which is currently being evaluated for the treatment of patients with chronic low-back pain.
Product Name : AlloStem
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 14, 2025
Lead Product(s) : CELZ-201
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CELZ-201
Therapeutic Area : Endocrinology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Creative Medical Reports One-Year Positive Results for AlloStem in T2D
Details : AlloStem (CELZ-201-DDT) is a cell and gene therapy drug candidate, which is currently being evaluated for the treatment of patients with Type 2 Diabetes.
Product Name : AlloStem
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 11, 2025
Lead Product(s) : CELZ-201
Therapeutic Area : Endocrinology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Discovery Platform
Sponsor : Greenstone Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Creative Medical Expands iPSCelz Collaboration with Greenstone Biosciences
Details : The collaboration aims to leverage Artificial Intelligence (AI) in further developing its human induced pluripotent stem cell (iPSC) platform for diabetes treatment.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
February 05, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Discovery Platform
Sponsor : Greenstone Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : CELZ-201
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CELZ-201-DDT Phase 1/2 Shows Positive Data in Chronic Back Pain
Details : AlloStem (CELZ-201-DDT) is a cell and gene therapy drug candidate, which is currently being evaluated for the treatment of patients with chronic low-back pain.
Product Name : AlloStem
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 30, 2025
Lead Product(s) : CELZ-201
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CELZ-201
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Creative Medical Advances FDA Cleared ADAPT Trial for CELZ-201 in Back Pain
Details : AlloStem (CELZ-201-DDT) is a cell and gene therapy drug candidate, which is currently being evaluated for the treatment of patients with chronic low-back pain.
Product Name : AlloStem
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 13, 2024
Lead Product(s) : CELZ-201
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Induced Pluripotent Stem Cell
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Creative Medical Technology Develops iPSCelz® to Produce Human Insulin
Details : iPSCelz is a human induced pluripotent stem cells (iPSC)-derived Islet Cells that produce human insulin, it is being investigated in patients with diabetes.
Product Name : iPSCelz
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 24, 2024
Lead Product(s) : Induced Pluripotent Stem Cell
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CELZ-201
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AlloStem (CELZ-201-DDT) is a cell and gene therapy drug candidate, which is currently being evaluated for the treatment of patients with chronic low-back pain.
Product Name : AlloStem
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 20, 2023
Lead Product(s) : CELZ-201
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amniotic Fluid Derived Stem Cell
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Creative Medical Technology Holdings Reports Positive Data on ImmCelz™ Immunotherapy Product
Details : ImmCelz™ has been demonstrated effective in animal models of autoimmunity and is currently the subject of a pending IND filed by the Company with the FDA for the treatment of stroke victims.
Product Name : ImmCelz
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 10, 2021
Lead Product(s) : Amniotic Fluid Derived Stem Cell
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OvaStem
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The findings, which are revealed in a newly filed patent application, show that T regulatory cells are effective in the treatment of ovarian failure, lending scientific support to OvaStem® as it approaches FDA clinical trials.
Product Name : OvaStem
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 02, 2021
Lead Product(s) : OvaStem
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable